Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with
docetaxel in patients with metastatic or locally recurrent breast cancer who have not
received chemotherapy treatment in the advanced disease setting.